Google Alert - cancer -horoscope

Google Alert – cancer -horoscope

Google Alert – cancer -horoscope

Lung cancer risk prediction model lacks efficacy in diverse populations https://www.google.com/url?rct=j&sa=t&url=https://www.healio.com/news/primary-care/20210409/lung-cancer-risk-prediction-model-lacks-efficacy-in-diverse-populations&ct=ga&cd=CAIyHGM0YWY4ZDI3MTA1YWI2ODA6Y28uaW46ZW46SU4&usg=AFQjCNFBR3j0bFgKginlYhlOJ9raCtz0eg
https://www.google.com/url?rct=j&sa=t&url=https://www.healio.com/news/primary-care/20210409/lung-cancer-risk-prediction-model-lacks-efficacy-in-diverse-populations&ct=ga&cd=CAIyHGM0YWY4ZDI3MTA1YWI2ODA6Y28uaW46ZW46SU4&usg=AFQjCNFBR3j0bFgKginlYhlOJ9raCtz0eg
<div class=”article__content–header”>
<div class=”article__posted-date”>
<p> April 09, 2021 </p>
<p> 2 min read </p>
</div>

</div>

<div class=”sources-disclosures”>
<a class=”title collapsed” data-toggle=”collapse” data-target=”.trustbox-toggle” aria-controls=”collapse-trust-box” data-module-track-category=”Healio NEWS” data-module-track-action=”Trust box expand_Click_Healio News Article” data-module-track-label=”Trust Box Expand_Healio News Article”>
<i class=”fas”></i>Source/Disclosures
</a>
<div class=”trustbox-toggle collapse” readability=”5.1376146788991″>

<div class=”disclosures” readability=”8″>
<strong> Disclosures: </strong>
Shusted reports no relevant disclosures. Please see the study for all other authors’ relevant financial disclosures.</div>
</div>
</div>
</div>
</div>
<div class=”col-12 col-md-6 offset-md-1 offset-xl-0 col-xl-12″>
<div class=”d-none” data-component=”EmailTopicAlert” data-module=”Subspecialty Email Topic Alerts Top” readability=”5.9605055292259″>
<hidden data-setting-item=”d265901d-6d37-49c7-a8f6-c7bf19a02509″></hidden>
<hidden data-crm-source=”News Subspecialty Topic Alert”></hidden>
<div class=”email-alert-button d-none” data-topic-button=”not-subscribed” readability=”7″>
<p>
<span data-module-track-action=”Email Alerts TOP_Click_Healio News Article” data-module-track-label=”Email Alerts TOP_Healio News Article”>
<i class=”fas fa-plus-circle”></i>
ADD TOPIC TO EMAIL ALERTS
</span>
</p>
<div class=”email-alert-inner collapse ud1bd1399778e49d48bc6c263662c755e” readability=”6″>
<div class=”email-alert-dialogue” readability=”8″>
<p>
Receive an email when new articles are posted on <span data-content=”topic-title”></span>
</p>
<div class=”d-none” data-sign-up-type=”unknown” readability=”7″>
Please provide your email address to receive an email when new articles are posted on <span data-content=”topic-title”></span>.

</div>
</div>
<button type=”button” class=”btn btn-primary” data-loading-text=”Loading <i class=’fa fa-spinner fa-spin’></i>” data-action=”subscribe”>
Subscribe
</button>
</div>
</div>
<div class=”email-alert-button d-none” data-topic-button=”subscribed”>
<p>
<i class=”fas fa-check-circle”></i>
ADDED TO EMAIL ALERTS
</p>

</div>

<div class=”d-none” data-topic-modal=”failed”> <strong>We were unable to process your request. Please try again later. If you continue to have this issue please contact <a href=”mailto:customerservice@slackinc.com”>customerservice@slackinc.com</a>.</strong> <p><button data-dismiss=”modal” class=”btn btn-primary btn-lg btn-block”>Back to Healio</button></p></div>
</div>
</div>
</div>
</div>
<p>A risk prediction model for lung cancer calculated scores that did not align with diagnoses in African American patients, according to results of a cross-sectional study.</p> <p>African American individuals are less often eligible for lung cancer screening based on <a href=”https://www.healio.com/news/hematology-oncology/20210219/disparities-in-lung-cancer-screening-may-persist-despite-revisions-to-uspstf-guideline” id=”rId15″ target=”_blank”>United States Preventive Services Task Force</a> criteria, <b>Christine S. </b><b>Shusted</b><b>, MPH,</b> a research data analyst at Thomas Jefferson University, and colleagues wrote in a research letter published in <i>JAMA Network Open</i>. </p><figure class=”figure article__og-image”>
<img src=”https://www.healio.com/~/media/slack-news/fm_im/misc/infographics/2021/april/pc0421shusted_graphic_01.jpg?h=630&w=1200&la=en&hash=8BCBADC1884E71AF80CD2BD4BCB7E49F” class=”figure-img img-fluid” alt=”Patients with screen-detected lung cancer who had PLCOm2012 risk scores in quartile 3 or 4: white patients, 61.1% vs. African American patients, 35.7%”>
<figcaption class=”figure-caption”>
Data derived from: Shusted CS, et al. JAMA Netw Open. 2021;doi:10.1001/jamanetworkopen.2021.4509.
</figcaption>
</figure> <p>“One approach to mitigate disparities in [lung cancer screening] eligibility is to use lung cancer risk prediction models to identify the patients with the highest risk,” they wrote. “Existing models have been derived from screening trials including 5% or fewer African American individuals and may not apply equitably to real-world screening participants.”</p> <p>Shusted and colleagues conducted a cross-sectional, single-center study that calculated the risk for lung cancer using the <a href=”https://www.healio.com/news/hematology-oncology/20201008/risk-prediction-model-may-reduce-racial-disparities-in-lung-cancer-screening-outcomes” id=”rId16″ target=”_blank”>Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial modified logistic regression model</a> (PLCOm2012) in 1,276 African American and white patients (mean age, 64.25 years; 42.7% African American; 59.3% women). There were “significant differences” in demographics between African American and white patients, with more African American patients being women (62.9% vs. 56.6%), smokers (63.9% vs. 49%) and Medicaid or dual-eligible beneficiaries (35.2% vs. 18.3%). African American patients were less likely to have private insurance only compared with white patients (25.3% vs. 33.2%). </p> <p>The researchers categorized patients into risk quartiles based on PLCOm2012 values in a screening cohort and a cancer cohort, which was comprised of patients who had screen-detected lung cancer, 44% of whom were African American. </p> <p>In the screening cohort, African American patients had a PLCOm2012 median risk score of 5.81%, which researchers wrote was “significantly higher” than median risk score of 4.1% in white patients. Additionally, more African American patients had risk scores in quartile 3 and 4 compared with white patients (59.8% vs. 42.5%), according to the researchers.</p> <p>However, among the cancer cohort, more white patients had a risk score in quartile 3 or 4 compared with African American patients (61.1% vs. 35.7%). </p> <p>“We found that lung cancer risk scores were not aligned with lung cancer diagnoses in African American patients,” researchers wrote. “Our findings suggest that we should use caution in applying risk models to diverse populations, given that our current understanding of lung cancer risk is incomplete.”</p>
<div class=”article__content–footer”>
<div class=”row”>
<div class=”col”>
<div class=”chips-group”>
<h3>Read more about</h3>

</div>
</div>
</div>
<div class=”d-none” data-component=”EmailTopicAlert” data-module=”Subspecialty Email Topic Alerts Bottom” readability=”5.9605055292259″>
<hidden data-setting-item=”d265901d-6d37-49c7-a8f6-c7bf19a02509″></hidden>
<hidden data-crm-source=”News Subspecialty Topic Alert”></hidden>
<div class=”email-alert-button d-none” data-topic-button=”not-subscribed” readability=”7″>
<p>
<span data-module-track-action=”Email Alerts BOTTOM_Click_Healio News Article” data-module-track-label=”Email Alerts BOTTOM_Healio News Article”>
<i class=”fas fa-plus-circle”></i>
ADD TOPIC TO EMAIL ALERTS
</span>
</p>
<div class=”email-alert-inner collapse ue4f5c604a5144f0fabb998c779bb0118″ readability=”6″>
<div class=”email-alert-dialogue” readability=”8″>
<p>
Receive an email when new articles are posted on <span data-content=”topic-title”></span>
</p>
<div class=”d-none” data-sign-up-type=”unknown” readability=”7″>
Please provide your email address to receive an email when new articles are posted on <span data-content=”topic-title”></span>.

</div>

<p><strong><a href=”https://blockads.fivefilters.org”></a></strong> <a href=”https://blockads.fivefilters.org/acceptable.html”>(Why?)</a></p> Fri, 09 Apr 2021 20:15:00 +0000
en
text/html
https://www.healio.com/news/primary-care/20210409/lung-cancer-risk-prediction-model-lacks-efficacy-in-diverse-populations

Secondary Cytoreduction Followed by Chemotherapy May Improve PFS in Ovarian Cancer https://www.google.com/url?rct=j&sa=t&url=https://www.cancernetwork.com/view/secondary-cytoreduction-followed-by-chemotherapy-may-improve-pfs-in-ovarian-cancer&ct=ga&cd=CAIyHGM0YWY4ZDI3MTA1YWI2ODA6Y28uaW46ZW46SU4&usg=AFQjCNHmr8x5QYz7mATVobjAsuAEzpQubA
https://www.google.com/url?rct=j&sa=t&url=https://www.cancernetwork.com/view/secondary-cytoreduction-followed-by-chemotherapy-may-improve-pfs-in-ovarian-cancer&ct=ga&cd=CAIyHGM0YWY4ZDI3MTA1YWI2ODA6Y28uaW46ZW46SU4&usg=AFQjCNHmr8x5QYz7mATVobjAsuAEzpQubA
<div><img src=”https://cdn.sanity.io/images/0vv8moc6/cancernetwork/f09b325ef728554fe8d7dec923d6b24518d9f3b4-4096×4096.jpg?auto=format” class=”ff-og-image-inserted”></div><p>For patients with platinum-sensitive relapsed ovarian cancer, research found that secondary cytoreduction followed by chemotherapy was associated with statistically significant longer progression-free survival (PFS) rates when compared to chemotherapy alone, according to data published in <em>Lancet Oncology</em>.</p><p>With these findings in mind, this cohort of patients should be counseled about the option of secondary cytoreduction as the standard of care at specialized centers, according to the research team.</p><p>“Secondary cytoreduction followed by chemotherapy improved progression-free survival with acceptable morbidity compared with chemotherapy alone for patients with platinum-sensitive, relapsed ovarian cancer selected using (international model) scores and PET-CT imaging,” wrote the investigators. “All patients should be counselled about the options of secondary cytoreduction in specialised centres with high volumes of ovarian cancer surgery.”</p><p>The multicenter, open-label, phase 3 SOC-1 trial (NCT01611766) enrolled 357 patients with platinum-sensitive relapsed ovarian cancer. The cohort was randomized, with 182 patients assigned to undergo secondary cytoreductive surgery followed by intravenous chemotherapy 175 patients assigned to chemotherapy alone. Median follow-up was 36 months.</p><p>Median PFS for patients in the surgery group was 17.4 months (95% CI, 15.0-19.8) compared with 11.9 months (95% CI, 10.0-13.8) for patients in the no surgery group (HR, 0.58; 95% CI, 0.45-0.74; <em>p</em> < .0001).</p><p>Median overall survival at the interim analysis was 58.1 months (95% CI, not estimable-not estimable) and 53.9 months (95% CI, 42.2-65.5) for patients in the surgery group and no surgery group, respectively (HR, 0.82; 95% CI, 0.57-1.19).</p><p>The safety profile featured 5% of patients in the surgery group experiencing grade 3-4 surgical morbidity at 30 days, with 0 patients in either group at 60 days after receiving their respective treatment.</p><p>Common grade 3-4 adverse events (AEs) during chemotherapy included neutropenia (17% of patients in the surgery group vs 12% of patients in the no surgery group), leucopenia (8% of patients vs 5% of patients), and anemia (6% of patients vs 6% of patients). A total of 4 serious AEs occurred in the surgery group, with no treatment-related deaths observed in the total patient population.</p><p>“Although data for overall survival is immature, the prespecified interim analysis of overall survival showed no difference between the surgery group and the no surgery group,” wrote the investigators. “Times to first and second subsequent anticancer therapy, which are key endpoints between progression-free survival and overall survival, were also longer in patients in the secondary cytoreduction plus chemotherapy group than in those in the chemotherapy alone.”</p><p>The major limitation of the data according to the research team is the 37% of patients who crossed over from the no surgery group to the surgery group at subsequent relapses. These relapses have the potential to extend the median overall survival data in the no surgery group, leading to a reduction in the statistical ability to detect a negative result.</p><p>Moving forward, the research team explains that longer-term survival outcomes need to be assessed with mature overall survival and treatment-free survival data.</p><p>“The results of this trial support the efficacy of secondary cytoreduction in patients with relapsed ovarian cancer selected using iMODEL scores and PET-CT imaging,” wrote the investigators.</p><p>Reference:</p><p>Shi T, Zhu J, Feng Y, et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. <em>Lancet Oncol</em> 2021. https://doi.org/10.1016/ S1470-2045(21)00006-1</p><p><strong><a href=”https://blockads.fivefilters.org”></a></strong> <a href=”https://blockads.fivefilters.org/acceptable.html”>(Why?)</a></p> Fri, 09 Apr 2021 19:52:30 +0000
en
text/html
https://www.cancernetwork.com/view/secondary-cytoreduction-followed-by-chemotherapy-may-improve-pfs-in-ovarian-cancer

Webinar on cancer prevention, treatment https://www.google.com/url?rct=j&sa=t&url=https://www.thehindu.com/news/cities/chennai/webinar-on-cancer-awareness-prevention/article34286152.ece&ct=ga&cd=CAIyHGM0YWY4ZDI3MTA1YWI2ODA6Y28uaW46ZW46SU4&usg=AFQjCNGATl-EJ-Mu4njx4CT8SEV3IGYWVA
https://www.google.com/url?rct=j&sa=t&url=https://www.thehindu.com/news/cities/chennai/webinar-on-cancer-awareness-prevention/article34286152.ece&ct=ga&cd=CAIyHGM0YWY4ZDI3MTA1YWI2ODA6Y28uaW46ZW46SU4&usg=AFQjCNGATl-EJ-Mu4njx4CT8SEV3IGYWVA
<div><img src=”https://www.thehindu.com/news/cities/chennai/kd4r4l/article34286150.ece/ALTERNATES/LANDSCAPE_615/10THRELACODE” class=”ff-og-image-inserted”></div><p> Rela Hospital will present <em>The Hindu </em>Wellness Series webinar on cancer prevention and treatment. </p><p>The webinar will bring to the table discussions on whether cancer can be prevented, the preventable risk factors, PET/CT scan investigation, how costly treatment cancer treatment can be, and the age factor for taking up mammogram tests. </p><p>The webinar would be held on Monday at 11.30 a.m. </p><p>The webinar would have on its panel Rela Hospital’s senior consultant Dr. Jagadesh Chandra Bose, nuclear medicine consultant Dr. Santhosh Sampath, and radiology consultant Dr. Komalavalli Subbiah. The webinar would be moderated by senior reporter Pon Vasanth B.A. </p><p>For participating in the webinar, register at: <a href=”https://apc01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fbit.ly%2FRELATHW&data=04%7C01%7Cramesh.v%40thehindu.co.in%7C8c81f3f4af7349f46fd608d8fb5f6cee%7Cc8f171fb8e124c1286ff9108c97b8963%7C0%7C0%7C637535734568370661%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=XImxnZinGEVNeN%2BRBdgV9fN%2BKpwveWLtr35prq9vqVI%3D&reserved=0″ title=”Original URL: http://bit.ly/RELATHW. Click or tap if you trust this link.”>http://bit.ly/ RELATHW</a> or scan the QR code. </p>
<p><strong><a href=”https://blockads.fivefilters.org”></a></strong> <a href=”https://blockads.fivefilters.org/acceptable.html”>(Why?)</a></p> Fri, 09 Apr 2021 19:30:00 +0000
en
text/html
https://www.thehindu.com/news/cities/chennai/webinar-on-cancer-awareness-prevention/article34286152.ece

Published at

HealthClot

Google Alert – cancer -horoscope

Leave a Reply Cancel reply